T1	intervention 52 91	sunitinib in combination with docetaxel
T2	control 99 114	docetaxel alone
T3	eligibility 249 352	patients with human epidermal growth factor receptor 2 (HER2)/neu-negative advanced breast cancer (ABC)
T4	outcome-Measure 619 650	Progression-free survival (PFS)
T5	intervention-participants 678 700	Two hundred ninety-six
T6	control-participants 761 764	297
T7	outcome 804 820	Median PFS times
T8	iv-cont-median 826 829	8.6
T9	cv-cont-median 834 844	8.3 months
T13	iv-bin-percent 1023 1026	55%
T14	cv-bin-percent 1051 1054	42%
T15	outcome 1077 1097	Duration of response
T16	iv-cont-median 1124 1134	7.5 months
T17	cv-cont-median 1158 1168	7.2 months
T18	outcome 1188 1222	Median overall survival (OS) times
T19	iv-cont-median 1228 1232	24.8
T20	cv-cont-median 1237 1248	25.5 months
T21	iv-bin-abs 1337 1340	107
T22	outcome 1341 1347	deaths
T23	cv-bin-abs 1373 1375	91
T10	outcome 946 975	objective response rate (ORR)
T11	outcome 1425 1445	adverse events (AEs)
T12	outcome 1582 1585	ORR
T24	outcome 1613 1622	PFS or OS
T25	outcome 1795 1798	AEs
